Jane Street’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.07M Buy
63,600
+19,600
+45% +$1.34M ﹤0.01% 4303
2025
Q4
$3.06M Buy
44,000
+11,800
+37% +$482K ﹤0.01% 4008
2025
Q3
$902K Sell
32,200
-12,000
-27% -$239K ﹤0.01% 6538
2025
Q2
$917K Buy
44,200
+5,000
+13% +$110K ﹤0.01% 5780
2025
Q1
$679K Buy
39,200
+19,300
+97% +$473K ﹤0.01% 6302
2024
Q4
$540K Sell
19,900
-15,700
-44% -$557K ﹤0.01% 6627
2024
Q3
$1.56M Sell
35,600
-156,400
-81% -$6.05M ﹤0.01% 4976
2024
Q2
$7.54M Buy
192,000
+21,100
+12% +$866K ﹤0.01% 2378
2024
Q1
$7.32M Buy
170,900
+125,700
+278% +$5.3M ﹤0.01% 2142
2023
Q4
$1.84M Buy
+45,200
New +$2.59M ﹤0.01% 4473

Other funds holding GPCR

Jane Street's GPCR Position: Q1 2026 in Review

Jane Street sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 147,217 shares — an estimated $10.1M sold.

Jane Street first reported a position in GPCR in Q4 2023 and held it in 7 quarters. The position peaked at $10.2M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Jane Street reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 147,217 Structure Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Jane Street first reported a position in Structure Therapeutics in Q4 2023 and held it in 7 quarters.
  • Jane Street's Structure Therapeutics position peaked at $10.2M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.